Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02259725 · ClinicalTrials.gov registry record · Phase 2
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
A Phase 2 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT02259725 is a Phase 2 study that has completed, run by University of Southern California. The registered enrollment target is 3 participants.
The verdict
NCT02259725, a Phase 2 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase II trial studies regorafenib in treating patients with neuroendocrine tumors that have spread from the primary site (place where it started) to other places in the body. Regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER laboratory biomarker analysis
- DRUG regorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2016-08-16 |
| Est. Completion | 2020-08-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02259725
The ClinicalTrials.gov registry entry for NCT02259725 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT02259725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02259725 about?
NCT02259725 is a clinical study titled "Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors". This phase II trial studies regorafenib in treating patients with neuroendocrine tumors that have spread from the primary site (place where it started) to other places in the body. Regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT02259725?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2016-08-16. Estimated completion is 2020-08-20.
What interventions are being tested in trial NCT02259725?
The interventions under investigation include: laboratory biomarker analysis (OTHER), regorafenib (DRUG).
Who is sponsoring clinical trial NCT02259725?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.